US FDA approves Syndax's blood cancer drug
FDA approved SNDX's drug for blood cancer treatment. SNDX shares rose 3% in after-hours trading.
View signal analysisCompany intelligence
SNDX
Syndax Pharmaceuticals, Inc. · NASDAQ · Healthcare
Price$19.99+0.36% · +$0.07
Market cap1.77BEquity value
P / E-8.0Trailing ratio
Volume271.66KLatest session
Market data
TradingViewSNDX price chart
Related signals
1 min delayedLatest SNDX price-moving signals
Browse public SNDX signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Wall Street Analysts Think Syndax (SNDX) Could Surge 50.26%: Read This Before Placing a Bet
SNDX closed at $23.50, gaining 18.2% in four weeks. Analysts project a mean price target of $35.31, indicating 50.3% upside. Analyst agreement on earnings revisions supports potential for stock upside. Zacks Consensus Estimate raised by 2.1% over the last month. SNDX holds a Zacks Rank #2, indicating strong buy sentiment.
View signal analysisResearch